Evidence map›Paper›PMID 40552158›Full record

ReviewFrontiers in pharmacology2025

Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.

Yutian Zhang, Tianlin Wang, Junquan Han, Jielin Song, Chaoshuai Yang, Lei Liang, Huizhen Li, Hong Wang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yutian Zhang *Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Tianlin Wang *Department of Gastroenterology, Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital, Tianjin, China.
Junquan HanDepartment of General Surgery, Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital, Tianjin, China.
Jielin SongGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Chaoshuai YangDepartment of General Surgery, Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital, Tianjin, China.
Lei LiangGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Huizhen LiDepartment of Gastroenterology, Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital, Tianjin, China.
Hong WangDepartment of General Surgery, Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disease with overnutrition and insulin resistance (IR) as the main etiologic factors. Hepatic lipid accumulation is a central factor contributing to this cascade of changes. Consequently, therapeutic interventions that target hepatic lipid metabolism and inflammatory response pathways hold considerable promise for the treatment of NAFLD. Furthermore, there is a close link between the gut microbiota (GM) and host health. GM and its metabolites can rely on multiple complex pathways to be deeply involved in the occurrence and development of NAFLD, which is associated with a variety of mechanisms. This makes it difficult to achieve satisfactory therapeutic efficacy of drugs targeting a single specific mechanism. In this context, natural products have the advantage of intervening in multiple targets and high safety. Consequently, an increasing number of researchers are considering natural products as a potential breakthrough point for the treatment of NAFLD. Notably, natural products influence intestinal mucosal permeability and metabolite production by regulating the abundance of beneficial flora in GM, which in turn regulates lipid metabolism to reduce hepatic steatosis and inhibit the progression of NAFLD. This paper reviews the research progress of natural products intervening in NAFLD through GM and its metabolites and lipid metabolism that has emerged in recent years, aiming to provide a basis for future natural product interventions in NAFLD.

Indexed as

gut microbiotalipid metabolismNAFLDnatural productsprobiotics

Identifiers

PMID40552158
PMCPMC12183287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.